Interleukin-17 serum levels as a vital indicator of psoriatic Iraqi patients in Thi-Qar Province
1
Citation
0
Reference
20
Related Paper
Citation Trend
Abstract:
Psoriasis is a multifactor skin disorder, with immune-mediated inflammatory pathogenesis. Theories and studies illustrated the crucial role for Interleukin-17 (IL-17) in promotes the occurrence and severity of psoriasis. We measured the serum IL-17 levels for detection the importance and effects of IL-17 as predictors for the psoriasis disorders and its severity. Forty-five cases of psoriatic patients and the same number from healthy subjects as control were included in this study, the severity of psoriasis was determined by the Psoriasis Area and Severity Index (PASI). Patients were categorize according to severity as mild psoriasis in (21), and moderate to severe psoriasis group in (24), 3 ml sera samples of both groups were collected to estimate IL-17, The results showed that the majority of the patients comprised of age group 36-45 (42.0%), Female to male ratio in patients was 1.6:1. Serum IL-17 was significantly increasing among psoriatic patients as compared to healthy controls (895.066 pg/ml and 364.334 pg/ml) respectively. Also, there was a relation between an elevated IL-17 serum levels and Psoriasis severity of groups with highly significant difference. It can be concluded that (IL-17) has important role during the activity of psoriasis and should be a target for biological therapy in Iraqi psoriatic patients.Keywords:
Pathogenesis
Interleukin 22
Interleukin-23
Cite
As a chronic inflammatory condition, psoriasis results from an interaction between genetic and immunologic factors in a predisposing environment. In spite of compelling evidence for the role of T cells and cytokines in psoriasis, interleukin (IL)-10 and IL-22 have not been sufficiently investigated.To assess the serum levels of IL-10 and IL-22 in patients with psoriasis compared to healthy controls.A total of 28 patients with psoriasis were compared with 28 age and sex-matched healthy subjects. Psoriasis Area and Severity Index (PASI) criteria were used to measure the severity of the disease. Serum levels of IL-10 and IL-22 were measured in both groups and compared.The mean serum level of IL-10 was 89.5±18.7 in patients compared to 117.2±23.4 pg/ml in the controls (p=0.36). Also, serum level of IL-22 was 284.1±49.7 in patients versus 425.4±82.8 pg/ml in control group (p=0.17). There was a significant direct correlation between levels of IL-10 and IL-22 in patients group (p=0.0005). The clinical severity of psoriasis was significantly correlated with high levels of IL-22 (p<0.0001).The direct correlation between higher levels of IL-22 and disease severity supports the clinical implication of this cytokine in psoriasis.
Interleukin 22
Cite
Citations (20)
Cite
Citations (0)
IntroductionPsoriasis is a T-cell-mediated inflammatory disease where T-helper (Th) lymphocytes (Th1, Th17, and Th22) play an important role in its pathogenesis. The aim of the present study was to assess the serum levels of interleukin (IL)-22 and its correlation with disease severity.Materials and methodsThe present study included 25 psoriatic patients and 25 healthy controls. Using serum samples collected from psoriatic patients and healthy controls, the concentrations of IL-22 were examined using ELISA kits. The severity of psoriatic skin lesions was assessed using psoriasis area and severity index scores.ResultsIL-22 concentrations were significantly higher in psoriatic patients in comparison with the control group. A significant, positive correlation between the concentrations of IL-22 and the severity of psoriasis was found.ConclusionThe results of our study suggest that Th22 along with its cytokine responses may contribute to the skin and systemic inflammatory conditions characteristic of psoriasis. It seems that early identification of soluble biomarkers and initiation of well-matched treatment may prevent exacerbation and progression of psoriasis.
Interleukin 22
Pathogenesis
Interleukin-23
Cite
Citations (5)
Objectives The aim of this study was to detect a relation between serum levels of interleukin-22 (IL-22) in patients with psoriasis and also to detect a relation of IL-22 with psoriasis area and severity index (PASI). Background IL-22 is highly expressed in several different chronic inflammatory conditions, including psoriasis, inflammatory bowel disease, and rheumatoid arthritis. The best studied function for IL-22 is within the skin, as it has an inflammatory role during skin inflammation. Materials and methods The study was conducted on 40 patients with psoriasis and 20 age-matched and sex-matched healthy individuals. All patients were subjected to history taking and complete medical examination. Serum levels of IL-22 were measured by enzyme-linked immunosorbent assay technique. Serum levels of IL-22 were statistically analyzed in relation to PASI. Results The serum levels of IL-22 were highly elevated in patients with psoriasis compared with healthy people (P Conclusion The significant elevation in the serum level of IL-22 in patients with psoriasis when compared with that of healthy controls and the significant elevation in the serum levels of IL-22 with advanced PASI score are suggestive of IL-22 playing a fundamental role in pathogenesis of psoriasis.
Pathogenesis
Medical History
Cite
Citations (0)
Psoriasis is a common, enigmatic, and recurrent disease. The precise etiology and pathogenesis of psoriasis are still unclear. Psoriasis has been treated as an inflammatory disorder related to an underlying Th1/Th17-dominated immune response. Interleukins are involved in the development of psoriasis lesions through Th-17-associated inflammation. Th1 and Th17 cytokines are found in skin lesions and in the peripheral blood of psoriasis patients. We sought to analyze serum levels of IL-1-β, IL-8, IL-9, IL-27, IL-29, IL-35, IFN-γ, TNF and TGF-β in patients with psoriasis and healthy control volunteers. Blood samples were collected from fifty-three patients with psoriasis and thirty-five healthy controls. Serum cytokines concentrations were determined using an enzyme-linked immunosorbent assay. Serum IL-8, IL-9, IL-27, IL-29 and TNF levels were statistically significant in psoriasis patients. Detectable serum IL-9 levels were found in 47 patients of the 53 in the psoriasis group. Interleukins-8, 27, 29 and TNF levels measured in the serum of psoriasis patients were slightly elevated as compared to healthy controls in a weakly significant way. On the other hand, there were highly significant differences in IL-9 levels between the two groups.
Pathogenesis
Etiology
Cite
Citations (29)
Background Psoriasis is a Th1/Th17 disease resulting from a dysregulated interplay between keratinocytes and immune cells, leading to skin hyperproliferation. Increased levels of interleukin (IL)-33 were reported in various Th1/Th17-driven autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease, with correlation to disease severity. Increased levels of IL-33 have been reported in lesional skin of psoriatic patients. The authors hypothesized that keratinocyte-released IL-33 might play a role in psoriasis pathogenesis; thus, inhibiting IL-33 activity might be a breaking new therapeutic strategy in its treatment. Patients and methods Serum IL-33 levels were measured by an enzyme-linked immunosorbent assay for 30 patients with active psoriasis (group A), 30 patient with stable psoriasis (group B), and 30 healthy age-matched and sex-matched controls (group C). Results Serum IL-33 showed statistically significant higher mean value among patients with psoriasis compared with the control group. The level of IL-33 in active psoriasis was significantly higher than in inactive psoriasis. Moreover, there was a statistically significant correlation between IL-33 and psoriasis area and severity index (PASI) score. Receiver operating characteristics curve detected the validity of serum IL-33 in differentiating patients with psoriasis from controls. At the cutoff point of IL-33 as 22.72 pg//ml, psoriasis could be predicted with 96.67% sensitivity and 93.33% specificity. Serum IL-33 was a statistically significant predictor of PASI score, with 63.5% of PASI scores predicted by serum IL-33. Conclusion Serum IL-33 may represent a new marker for psoriasis diagnosis as well as a predictor of the disease severity.
Interleukin 1β
Cite
Citations (1)
Previous studies correlating Th1 and Th2 cytokine profiles with psoriasis activity provided inconsistent results. Correlation of tissue cytokine levels with psoriasis severity has not been studied till now.To compare serum and tissue Th1 and Th2 cytokine profiles of patients with active and stable psoriasis as well as healthy controls, and to correlate them with psoriasis severity.This was a cross-sectional study involving adult patients with 'active' psoriasis (untreated progressive chronic plaque psoriasis, guttate psoriasis, and erythrodermic psoriasis), 'stable' psoriasis (stable plaque psoriasis or those with completely resolved lesions) and healthy subjects with non-inflammatory skin lesions as controls. Mean levels of Th1 and Th2 cytokines in serum [interleukin 2 (IL-2), interferon-gamma (IFN-γ), IL-4, IL-10] and tissue mRNA expression (IFN-γ, IL-4) were compared among these three groups.There were 30 patients each in active and stable psoriasis groups, and 15 in the control group. Mean serum IL-2, IFN-γ, and IL-10 levels of patients with psoriasis patients were significantly higher than the controls (P < 0.001 for both active and stable psoriasis), whereas mean serum IL-4 level of patients was significantly lower than the controls (P < 0.001). However, there was no statistically significant difference of serum cytokine levels between active and stable psoriasis groups. Mean quantitative tissue mRNA expression of IFN-γ and IL-4 of patients with active and stable psoriasis were significantly lower than the controls (P < 0.001 and <0.01, respectively), but were not significantly different between active and stable psoriasis groups. Serum and tissue cytokines showed weak correlation with psoriasis area and severity index.Small sample size and heterogenous nature of patients with psoriasis in terms of disease activity, morphology and treatment are limitations of this study.There is no significant change in the serum or tissue levels of Th1 and Th2 cytokines with activity or severity of psoriasis.
Cite
Citations (21)
Studies investigating systemic inflammation in psoriasis use different serum markers and report discrepant results. We set out to determine whether systemic inflammation is elevated in patients with psoriasis compared with healthy controls, and to measure the extent of this elevation, by summarizing available data on serum inflammatory markers. PubMed, Embase and Web of Science were searched from inception to March 2011. We included studies comparing the serum inflammatory markers interleukin (IL)-1β, IL-6, IL-10, C-reactive protein (CRP), intracellular adhesion molecule (ICAM)-1, E-selectin and tumour necrosis factor (TNF)-α in patients with psoriasis and healthy controls. Differences in serum marker levels between patients and controls were pooled as standardized mean differences (SMDs; Cohen's d) using a random-effects model. Seventy-eight studies were eligible. Of the 7852 individuals included, 3085 had (severe plaque) psoriasis. The pooled SMDs were higher in patients with psoriasis than in healthy controls for IL-6 [d = 1·32, 95% confidence interval (CI) 0·83–1·81], CRP (d = 1·83, 95% CI 0·76–2·90), TNF-α (d = 1·32, 95% CI 0·86–1·79), E-selectin (d = 1·78, 95% CI 1·32–2·25) and ICAM-1 (d = 1·77, 95% CI 1·15–2·39). The SMD between cases and controls for IL-1β and IL-10 was not significant. Age had a significant effect on the SMD for IL-6 and TNF-α. For IL-6 the effect size was higher for plaque psoriasis studies (d = 1·98). The effect size was not influenced by the Psoriasis Area and Severity Index, measurement method or quality assessment. The pooled analyses suggest modest but significantly elevated levels of the proinflammatory cytokines in the serum of patients with psoriasis with predominantly severe disease. To what extent this modest increment is clinically relevant could be investigated in a synthesis of all studies measuring inflammation before and after antipsoriatic therapy.
Cite
Citations (240)
Interleukin 16 (IL-16) has been described as a significant cytokine involved in the recruitment of CD4+ cells during inflammation; however, its potential role in psoriasis has not been defined. Our aim was to investigate the IL-16 serum levels and IL-16 mRNA skin expression in psoriasis patients in correlation with disease severity and mRNA skin expression for CD4. Moreover, the IL-16 skin localization was assessed and the -295 T/C IL-16 polymorphism was analyzed. For this exploratory, observational, and cross-sectional study, 97 unrelated patients with chronic plaque type psoriasis and 104 healthy controls were enrolled. IL-16 serum levels were significantly increased in patients compared with controls (P = 0.000022) and positively correlated with Psoriasis Area and Severity Index (r = 0.34, P = 0.0007), Body Surface Area (r = 0.34, P = 0.01) and were significantly higher in individuals with moderate to severe psoriasis (P = 0.0029). There was no significant correlation between IL-16 serum levels and Dermatology Quality of Life Index and no differences in genotype and allele frequencies for -295 T/C IL-16 polymorphism. The expression of IL-16 (mRNA and protein) was elevated in the margin of psoriatic skin while statistically significant increase in IL-16 immunoreactivity, but not in mRNA level, was observed within plaques. Furthermore, the IL-16 mRNA levels within psoriatic lesions positively correlated with the levels of CD4 mRNA, but not with Psoriasis Area and Severity Index. In conclusion, our data revealed an association between circulating IL-16 and severity of psoriasis which indicates that this cytokine could serve as a potential marker of disease activity. However, further investigations are required.
Body surface area
Cite
Citations (21)
Psoriasis is a T cell-mediated inflammatory disease in which pathogenesis T helper (Th) lymphocytes (Th1, Th17, and Th22) play an important role. The aim of the study was to assess the serum levels of some cytokines involved in the Th17 and Th22 responses in psoriatic patients.The study comprised 60 psoriatic patients and 30 healthy controls. In the serum collected from psoriatic patients and healthy controls, the concentrations of IL-6, IL-12, IL-17, IL-20, IL-22, and IL-23 were examined with ELISA kits. Severity of psoriatic skin lesions was assessed by means of PASI, BSA, and PGA scores.IL-6, IL-20, and IL-22 concentrations were significantly higher in psoriatic patients in comparison with the control group. The positive correlations between the concentrations of IL-22 and IL-20 and severity of psoriasis assessed with PASI and BSA scores as well as IL-17 and PASI score were found. There was also a positive correlation between IL-23 and IL-17 concentrations.Results of the conducted studies suggest that Th22 response may contribute to the skin and systemic inflammatory disease in psoriasis. It seems that early identification of soluble biomarkers and initiation of well-matched treatment may prevent exacerbation and progression of psoriasis.
Interleukin 22
Pathogenesis
Interleukin-23
Cite
Citations (100)